PIPELINE

 

TBX-3400 FOR SOLID TUMORS

Highlights

Taiga’s TBX-3400 is currently being tested in human clinical trials as a treatment for various solid tumors. Due to the agnostic nature of TBX-3400, a variety of solid tumors are being tested.


We have one active clinical trial evaluating TBX-3400 against solid tumors and plan to initiate two additional trials by the end of the year.

  • Received Orphan Drug Designation from the U.S. FDA for the treatment of malignant melanoma stages IIB to IV.

  • Safety Data from a colorectal cancer trial showed no severe adverse events and has been approved by the Japanese Ministry of Health, Labor and Welfare.

 

TBX-3400 FOR INFECTIOUS DISEASE

Taiga’s TBX-3400 is currently being tested in human clinical trials as a treatment for various infectious diseases. 
 

Many infectious diseases can further develop into cancer, particularly hepatitis B’s progression to hepatocellular carcinoma and HPV’s association with head and neck cancer. Taiga’s goal is to provide treatment for the infectious disease prior to disease progression.

 

TBX-2400 FOR BONE MARROW TRANSPLANTS

Highlights

  • Received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency.

  • Received Advanced Therapy Medicinal Product from the European Medicines Agency.

  • Granted Rare Pediatric Disease Designation by the U.S. FDA.

Taiga will be launching its first clinical trial for TBX-2400 by the end of the year in adult patients with either myelofibrosis or acute myeloid leukemia. A clinical trial for pediatric patients is projected to begin in the next twelve months.

 

RED BLOOD CELLS

We have developed a process to treat donated blood products with our protein that enables the blood products to maintain stability while stored at 37°C for an extended period of time, removing the need for cold storage.


Possible areas where this technology may be used:

  • National Defense applications

  • Natural Disaster applications

  • Storage of rare blood types

In addition, we have developed a method to produce an almost unlimited supply of red blood cells in the laboratory. Preclinical studies have shown that these red blood cells maintain function similar to naturally produced red blood cells.

 

HEMATOPOIETIC STEM CELLS

We are developing methods to expand hematopoietic stem cells ex vivo for use in stem cell transplantation and drug screening.

 

This technology is in preclinical development, yet has shown promise of accelerating the expansion of stem cells.